ClinicalTrials.gg
CompletedNCT01248468Updated Jul 30, 2012Results posted

Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine

A Phase 4 interventional study of Aspirin, acetaminophen and caffeine and Sumatriptan in Pain, Migraine, sponsored by Novartis. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-30.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
752
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.

Enrollment
4th of 137
752 · median 95
Started
2010
with 5 others
Phase 4
67 of 137
5 open now
Registered
36th of 137
by date

Among the 137 studies testing acetaminophen in Pain, this one is the 4th largest by enrollment, is one of 6 that started in 2010, is one of 67 in phase 4, and was the 36th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies testing acetaminophen in Pain, or all of them as a file.
02

Study summary

The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.

03

Conditions studied

  • Pain, Migraine

Keywords

  • Pain, Migraine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18 years and over.
  2. International Headache Society (IHS) diagnosis of migraine without aura or typical aura with migraine headache.
  3. History of experiencing at least 1, but not more than 8, acute migraine attacks monthly during the previous year.
  4. History of at least moderate migraine pain intensity, if left untreated.

Exclusion criteria

Exclusion criteria:

  1. Headache symptoms which may be due to or aggravated by:

    • Recent (within 6 months) head or neck trauma (e.g., whiplash)
    • Head or neck pain secondary to an orthopedic abnormality
    • Cluster headache
    • Specific migraine variants (e.g., basilar-type artery migraine, ophthalmoplegic migraine, hemiplegic migraine, migraine aura without headache)
    • Other serious, non-migraine causes of headache (e.g., increased intracranial pressure, intracranial bleeding, meningitis, )
    • Non-serious, non-migraine causes of headache (e.g., cold, flu, hangover)
  2. Routine use (≥ 10 days per month, on average) of any medication having the potential to interfere with the pharmacologic effects or evaluation of the study medications (e.g., narcotic and non-narcotic analgesic products (prescription or over-the-counter), ergotamine-containing and ergot-type medication, anxiolytics, hypnotics, sedatives, 5HT-1 agonists, anti-emetics, or prokinetic drugs).
  3. History of vomiting during more than 20% of migraine episodes or confined to bedrest for more than 50% of migraine episodes.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
752 participants (actual)

Study arms

  • Experimental
    Aspirin, acetaminophen and caffeine

    AAC: 2 tablets, each containing acetaminophen 250 mg, aspiring 250 mg, caffeine 65 mg and 1 placebo tablet matching sumatriptan 100 mg tablets

    Drug: Aspirin, acetaminophen and caffeine

  • Active comparator
    Sumatriptan (100 mg)

    1 tablet containing sumatriptan 100 mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets

    Drug: Sumatriptan

  • Placebo comparator
    Placebo

    1 placebo tablet matching sumatriptan 100mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets

    Drug: Placebo

Interventions

  • DrugAspirin, acetaminophen and caffeine

    Drug pages: Aspirin · Acetaminophen · Caffeine

    2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)

  • 100 mg Sumatriptan

  • DrugPlacebo

    placebo

06

What researchers measure

Primary outcomes

  1. Percent of Subjects Who Are Pain Free at 2 Hours.

    Subjects assessed severity of pain on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of pain=none at 2 hours were considered pain free at 2 hours

    Time frame: 2 hours

Secondary outcomes

  1. Percent of Subjects Who Are Free of Nausea at 2 Hours.

    Subjects assessed severity of relevant symptom on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of relevant symptom=none at 2 hours were considered relevant symptom free at 2 hours

    Time frame: 2 hours

  2. Percent of Subjects Who Are Free of Phonophobia at 2 Hours.

    Subjects assessed severity of relevant symptom on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of relevant symptom=none at 2 hours were considered relevant symptom free at 2 hours

    Time frame: 2 hours

  3. Percent of Subjects Who Are Free of Photophobia at 2 Hours.

    Subjects assessed severity of relevant symptom on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of relevant symptom=none at 2 hours were considered relevant symptom free at 2 hours

    Time frame: 2 hours

07

Results

Posted Jul 30, 2012

Participant flow

Participant flow — Overall Study
MilestoneAspirin, Acetaminophen, and CaffeineSumatriptan (100 mg)Placebo
Started299304149
Safety population266271133
Itt population256261125
Completed284290145
Not completed15144
Withdrew: Administrative problem100
Withdrew: Lost to follow-up9124
Withdrew: Pregnancy100
Withdrew: Withdrawal by subject420

Outcome measures

PrimaryPercent of Subjects Who Are Pain Free at 2 Hours.

Subjects assessed severity of pain on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of pain=none at 2 hours were considered pain free at 2 hours

Time frame:
2 hours
Reported as:
Number · Percent of participants
Percent of Subjects Who Are Pain Free at 2 Hours.
Percent of participantsAspirin, Acetaminophen, and CaffeineSumatriptan (100 mg)Placebo
Percent of Subjects Who Are Pain Free at 2 Hours.34.7 (.938 to 2.484)44.9 (0.431 to .900)26.4 (1.525 to 3.937)
SecondaryPercent of Subjects Who Are Free of Nausea at 2 Hours.

Subjects assessed severity of relevant symptom on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of relevant symptom=none at 2 hours were considered relevant symptom free at 2 hours

Time frame:
2 hours
Reported as:
Number · percent of participants
Percent of Subjects Who Are Free of Nausea at 2 Hours.
percent of participantsAspirin, Acetaminophen, and CaffeineSumatriptan (100 mg)Placebo
Percent of Subjects Who Are Free of Nausea at 2 Hours.70.6 (.863 to 2.522)72.2 (.662 to 1.506)66.4 (.856 to 2.549)
SecondaryPercent of Subjects Who Are Free of Phonophobia at 2 Hours.

Subjects assessed severity of relevant symptom on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of relevant symptom=none at 2 hours were considered relevant symptom free at 2 hours

Time frame:
2 hours
Reported as:
Number · Percent of participants
Percent of Subjects Who Are Free of Phonophobia at 2 Hours.
Percent of participantsAspirin, Acetaminophen, and CaffeineSumatriptan (100 mg)Placebo
Percent of Subjects Who Are Free of Phonophobia at 2 Hours.53.4 (.904 to 2.353)60.9 (.630 to 1.334)46.2 (.977 to 2.590)
SecondaryPercent of Subjects Who Are Free of Photophobia at 2 Hours.

Subjects assessed severity of relevant symptom on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of relevant symptom=none at 2 hours were considered relevant symptom free at 2 hours

Time frame:
2 hours
Reported as:
Number · Percent of participants
Percent of Subjects Who Are Free of Photophobia at 2 Hours.
Percent of participantsAspirin, Acetaminophen, and CaffeineSumatriptan (100 mg)Placebo
Percent of Subjects Who Are Free of Photophobia at 2 Hours.48.6 (.888 to 2.327)52.3 (.631 to 1.315)40.8 (.980 to 2.542)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aspirin, Acetaminophen, and Caffeine—0/266 (0%)8/266 (3%)
Sumatriptan (100 mg)—0/271 (0%)14/271 (5.2%)
Placebo—0/133 (0%)3/133 (2.3%)
Most frequent other events
Most frequent other events
EventAspirin, Acetaminophen, and CaffeineSumatriptan (100 mg)Placebo
NauseaGastrointestinal disorders8/26614/2713/133

Baseline characteristics

Age Continuous
Age Continuous(years)Aspirin, Acetaminophen, and CaffeineSumatriptan (100 mg)PlaceboTotal
Mean38 ± 11.437.8 ± 11.437.6 ± 11.537.8 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Aspirin, Acetaminophen, and CaffeineSumatriptan (100 mg)PlaceboTotal
Female250245125620
Male495924132
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aspirin, Acetaminophen, and CaffeineSumatriptan (100 mg)PlaceboTotal
American Indian or Alaska Native1102
Asian39517
Native Hawaiian or Other Pacific Islander1203
Black or African American444724115
White244239113596
Other66719
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Aspirin, Acetaminophen, and CaffeineSumatriptan (100 mg)PlaceboTotal
United States299304149752
08

Study locations

20 sites
  • Anaheim, California, United States
  • San Francisco, California, United States
  • Clearwater, Florida, United States
  • Deland, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Pembroke Pines, Florida, United States
  • West Palm Beach, Florida, United States
  • Chicago, Illinois, United States
  • Ann Arbor, Michigan, United States
  • Springfield, Missouri, United States
  • Bronx, New York, United States
  • Rochester, New York, United States
  • Raleigh, North Carolina, United States
  • Cleveland, Ohio, United States
  • Mount Pleasant, South Carolina, United States
  • Nashville, Tennessee, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Seattle, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2010
First posted
Nov 25, 2010
Start
Nov 2010
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Jul 30, 2012
Last update
Jul 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01248468
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Nov 25, 2010
Start date
Nov 2010
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Jul 30, 2012
Last update
Jul 30, 2012

Study contacts

Clinical Project Leader
study director · Novartis Consumer Health

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Acetaminophen · Caffeine

Start the discussion